

Evonik Financials & ESG KPI's

Financial KPI Group	P. 2
ESG KPI Group	P. 3
Division KPI	P. 4-8
Group Income Statement	P. 9-10
Group Balance Sheet	P. 11
Group Cash Flow Statement	P. 12
Group Net Financial Position	P. 13
Definitions	P. 14

As of Q3 2020 (03 November 2020)
(Financials for FY2015 & FY2016 available in hidden columns in Excel file)

Financial KPI Group

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
External Sales	14,383	13,267	3,287	3,306	3,232	9,824	3,284	13,108	3,243	2,827	2,917	8,986
<i>Growth (%)</i>	13%	4%	1%	-3%	-3%	-2%	1%	-1%	-1%	-14%	-10%	-9%
<i>Volumes (%)</i>	3%	1%	0%	-2%	-3%	-1%	0%	-1%	-1%	-12%	-5%	-6%
<i>Prices (%)</i>	2%	5%	1%	0%	-2%	-1%	-4%	-2%	-2%	-3%	-2%	-3%
<i>Exchange Rates (%)</i>	-1%	-3%	0%	-1%	2%	0%	1%	1%	0%	0%	-4%	-1%
<i>Other (incl. M&A; %)</i>	9%	1%	0%	0%	0%	0%	4%	1%	2%	1%	1%	1%
Adjusted EBITDA	2,357	2,150	539	566	543	1,647	505	2,153	513	456	519	1,488
<i>Margin (%)</i>	16.4%	16.2%	16.4%	17.1%	16.8%	16.8%	15.4%	16.4%	15.8%	16.1%	17.8%	16.6%
EBIT	1,225	1,049	296	319	219	834	252	1,086	247	188	245	680
Adjusted EBIT	1,486	1,361	315	340	293	948	253	1,201	273	202	269	744
<i>Margin (%)</i>	10.3%	10.3%	9.6%	10.3%	9.1%	9.6%	7.7%	9.2%	8.4%	7.1%	9.2%	8.3%
Adjusted EPS	2.16	2.18	0.53	0.49	0.42	1.44	0.50	1.94	0.39	0.34	0.40	1.13
Free Cash Flow ¹	511	526	159	-64	321	417	300	717	113	96	312	521
Capex (Cash outflow for investment in intangible assets, pp&e)	1,040	948	175	182	210	567	313	880	184	189	223	596
Capital employed (annual average)	13,257	13,299						14,035				
ROCE (%)	11.2%	10.2%						8.6%				
Dividend (€)	1.15	1.15						1.15				
Employees (continuing operations)	36,523	32,623	32,522	32,370	32,570	32,570	32,423	32,423	32,770	32,621	32,822	32,822

¹ Excl. extraordinary carve-out taxes of -€128 m in Q3 2019 (related to MMA divestment)

KPI Environment, Social, Governance

	Year FY 2017	Year FY 2018	Year FY 2019
Strategy & Growth			
<i>Sales share with "Next Generation Solutions"</i>			>30%
Governance & Compliance			
<i>Women at the first management level below the executive board</i>	25%	27%	26%
<i>Women at the second management level below the executive board</i>	15%	20%	24%
<i>Training rate antitrust law</i>	59%	74%	82%
<i>Training rate fighting corruption</i>	84%	83%	91%
<i>Training rate code of conduct</i>	71%	77%	89%
<i>Internal investigations</i>	27	90	113
<i>Disciplinary measures</i>	12	106	60
Value Chain & Products			
<i>Use of renewable resources in production</i>	10%	10%	8%
<i>Raw material suppliers covered by TfS assessments</i>			66%
<i>No. of sustainability audits (Evonik/TfS)</i>	469	380	335
<i>No. of sustainability assessments (Evonik/TfS)</i>	1,943	1,621	1,160
<i>R&D expenses (€ million)</i>	476	459	428
The environment			
<i>Scope 1 greenhouse gas emissions (million metric tons CO2)</i>	5.6	5.7	4.9
<i>Scope 2 greenhouse gas emissions (million metric tons CO2)</i>	0.9	0.9	0.6
<i>Scope 3 greenhouse gas emissions (million metric tons CO2)</i>	20.4	21.0	
<i>Total water intake (in million m³)</i>	504	490	535
<i>Specific water intake (in m³ freshwater / metric ton production)</i>	32.3	31.8	32.1
<i>Production waste (thousand metric tons)</i>	396	393	321
Employees			
<i>Early employee turnover</i>	1.4%	0.9%	0.9%
<i>Continuing professional development per employee (hours)</i>	12	16	8
<i>Female managers (management circles 1-3)</i>	23%	24%	25%
<i>Occupational health performance index</i>	5.4	5.5	5.5
Safety			
<i>Accident frequency rate (no. of accidents / 1 million working hours)</i>	1.16	0.87	1.18
<i>Incident frequency rate (no. of accidents / 1 million working hours)</i>	1.11	1.08	1.10

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

Specialty Additives

in € million	Year FY 2017 ¹	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	3,244	3,380	842	867	861	2,571	810	3,381	852	747	777	2,377
<i>Growth (%)</i>	53%	4%	1%	-3%	2%	0%	0%	0%	1%	-14%	-10%	-7%
<i>Volumes (%)</i>	4%	3%	-1%	-4%	1%	-1%	-1%	-1%	1%	-15%	-6%	-6%
<i>Prices (%)</i>	2%	3%	1%	2%	-1%	1%	0%	1%	0%	1%	0%	0%
<i>Exchange Rates (%)</i>	-1%	-2%	1%	-1%	2%	1%	1%	0%	0%	0%	-4%	-1%
<i>Other (incl. M&A; %)</i>	48%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Adjusted EBITDA	857	908	225	226	232	683	203	886	239	202	214	656
<i>Margin (%)</i>	26.4%	26.9%	26.7%	26.1%	26.9%	26.6%	25.1%	26.2%	28.1%	27.0%	27.5%	27.6%
EBIT	n.a.	n.a.	184	184	187	555	157	712	196	160	171	527
Adjusted EBIT	676	744	184	184	189	558	158	716	196	158	171	525
<i>Margin (%)</i>	20.8%	22.0%	21.9%	21.2%	22.0%	21.7%	19.5%	21.2%	23.0%	21.2%	22.0%	22.1%
Capital expenditures	92	75	16	21	26	62	46	108	13	19	21	52
Capital employed (annual average)	3,494	3,912						3,956				
ROCE (%)	19.4%	19.0%						18.1%				
Employees	n.a.	n.a.	3,646	3,642	3,665	3,665	3,651	3,651	3,631	3,610	3,649	3,649

¹ First-time consolidation of acquired Air Products businesses as of 3 January 2017. Impact on sales: ~€1 bn; adj. EBITDA: ~€215 m

Nutrition & Care

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	3,002	3,036	731	719	726	2,176	747	2,922	748	742	715	2,205
Growth (%)	-5%	1%	0%	-7%	-5%	-4%	-2%	-4%	2%	3%	-2%	1%
Volumes (%)	4%	5%	8%	-1%	-4%	1%	2%	1%	3%	1%	-2%	0%
Prices (%)	-12%	1%	-7%	-5%	-3%	-5%	-5%	-5%	-1%	4%	8%	4%
Exchange Rates (%)	-1%	-5%	-1%	-1%	2%	0%	1%	0%	0%	-2%	-8%	-3%
Other (incl. M&A; %)	4%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Sales Animal Nutrition	1,564	1,574	374	353	345	1,072	365	1,438	398	384	330	1,112
Sales Health & Care	1,438	1,462	357	365	381	1,103	381	1,484	350	358	385	1,093
Adjusted EBITDA	498	550	113	121	119	353	109	462	118	168	140	427
Margin (%)	16.6%	18.1%	15.5%	16.8%	16.4%	16.2%	14.6%	15.8%	15.8%	22.6%	19.6%	19.4%
EBIT	n.a.	n.a.	63	68	43	174	33	207	54	104	59	216
Adjusted EBIT	319	362	64	71	52	188	44	231	54	106	79	239
Margin (%)	10.6%	11.9%	8.8%	9.9%	7.2%	8.6%	5.9%	7.9%	7.2%	14.2%	11.0%	10.8%
Capital expenditures	338	442	35	65	45	145	69	214	18	24	36	79
Capital employed (annual average)	2,664	2,808						3,079				
ROCE (%)	12.0%	12.9%						7.5%				
Employees	n.a.	n.a.	5,427	5,410	5,339	5,339	5,322	5,322	5,280	5,271	5,257	5,257

Smart Materials

in € million	Year FY 2017 ¹	Year FY 2018 ¹	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	3,148	3,382	857	845	833	2,535	836	3,371	858	722	790	2,369
Growth (%)	1%	7%	4%	-2%	-1%	0%	-3%	0%	0%	-15%	-5%	-7%
Volumes (%)	7%	-3%	-3%	-5%	-5%	-4%	-6%	-4%	-4%	-20%	-7%	-11%
Prices (%)	1%	7%	7%	4%	3%	5%	-1%	3%	-1%	0%	-2%	-1%
Exchange Rates (%)	-1%	-2%	0%	0%	1%	0%	1%	0%	0%	0%	-4%	-1%
Other (incl. M&A; %)	-6%	5%	0%	-1%	0%	0%	3%	1%	5%	5%	8%	6%
Sales Inorganics	2,117	2,325	585	576	567	1,728	584	2,312	597	528	566	1,691
Sales Polymers	1,031	1,057	272	269	266	807	252	1,059	260	193	224	677
Adjusted EBITDA	565	631	162	164	157	483	168	651	166	102	137	405
Margin (%)	17.9%	18.7%	18.9%	19.4%	18.8%	19.1%	20.1%	19.3%	19.3%	14.1%	17.3%	17.1%
EBIT	n.a.	n.a.	107	107	102	316	128	443	90	30	63	183
Adjusted EBIT	415	434	110	112	99	321	112	433	108	34	73	215
Margin (%)	13.2%	12.8%	12.8%	13.3%	11.9%	12.7%	13.4%	12.8%	12.6%	4.7%	9.2%	9.1%
Capital expenditures	286	243	36	53	72	161	142	303	83	98	105	286
Capital employed (annual average)	2,226	2,565						2,702				
ROCE (%)	18.6%	16.9%						16.0%				
Employees	n.a.	n.a.	7,141	7,154	7,145	7,145	7,065	7,065	7,615	7,607	7,610	7,610

¹ First-time consolidation of acquired Huber business as of 1 September 2017. Annual contribution to sales: ~€300 m; adj. EBITDA: ~€60 m

Performance Materials

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	2,609	2,789	677	698	607	1,981	652	2,634	584	437	444	1,466
<i>Growth (%)</i>	11%	7%	-3%	-2%	-17%	-7%	0%	-6%	-14%	-37%	-27%	-26%
<i>Volumes (%)</i>	-2%	-1%	-2%	0%	-5%	-2%	8%	0%	-6%	-17%	-7%	-10%
<i>Prices (%)</i>	14%	9%	0%	-2%	-10%	-4%	-15%	-7%	-8%	-20%	-20%	-16%
<i>Exchange Rates (%)</i>	-1%	-2%	0%	0%	1%	0%	2%	1%	0%	0%	0%	0%
<i>Other (incl. M&A; %)</i>	0%	1%	-1%	0%	-3%	-1%	5%	0%	0%	0%	0%	0%
Adjusted EBITDA	290	243	63	84	49	195	53	248	18	12	28	57
<i>Margin (%)</i>	11.1%	8.7%	9.3%	12.0%	8.1%	9.8%	8.1%	9.4%	3.1%	2.7%	6.3%	3.9%
EBIT	n.a.	n.a.	16	51	16	84	17	101	-12	-21	-5	-39
Adjusted EBIT	201	158	26	52	17	94	22	117	-12	-21	-5	-39
<i>Margin (%)</i>	7.7%	5.7%	3.8%	7.4%	2.8%	4.7%	3.4%	4.4%	-2.1%	-4.8%	-1.1%	-2.7%
Capital expenditures	92	57	12	14	11	37	18	55	10	9	11	30
Capital employed (annual average)	818	919						1,007				
ROCE (%)	24.5%	17.2%						11.6%				
Employees	n.a.	n.a.	1,653	1,640	1,669	1,669	1,645	1,645	1,656	1,652	1,640	1,640

Services, Corporate & Other

Services and Corporate & Other will be reported and guided as only one combined division going forward (in IR documents)

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	712	680	180	177	205	561	239	800	201	179	191	569
<i>Growth (%)</i>	2%	-4%						18%	12%	1%	-7%	1%
Adjusted EBITDA	-238	-182	-24	-29	-14	-67	-27	-94	-28	-28	0	-57
EBIT	n.a.	n.a.	-74	-91	-129	-295	-83	-377	-81	-85	-43	-207
Adjusted EBIT	-378	-336	-69	-79	-64	-213	-82	-296	-73	-75	-49	-196
Capital expenditures	173	151	25	33	43	102	60	162	74	43	43	160
Employees	n.a.	n.a.	14,655	14,523	14,752	14,752	14,740	14,740	14,588	14,481	14,666	14,666

Group Income Statement

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	14,383	13,267	3,287	3,306	3,232	9,824	3,284	13,108	3,243	2,827	2,917	8,986
Cost of sales	-9,905	-9,271	-2,312	-2,332	-2,343	-6,986	-2,427	-9,413	-2,324	-2,002	-2,104	-6,430
Gross profit on sales	4,478	3,996	975	974	889	2,838	857	3,695	919	825	813	2,556
Selling expenses	-1,695	-1,563	-380	-385	-370	-1,135	-376	-1,511	-394	-368	-350	-1,112
Research and development expenses	-476	-437	-107	-101	-107	-315	-113	-428	-109	-103	-104	-317
General administrative expenses	-714	-599	-148	-136	-135	-419	-149	-568	-125	-128	-121	-374
Other operating income & expenses	-378	-358	-34	-38	-60	-309	25	-107	-49	-40	1	-256
Result from investments recognized at equity	10	10	-10	5	2	-3	8	5	5	2	6	13
Income before financial result and income taxes, continuing operations = EBIT	1,225	1,049	296	319	219	834	252	1,086	247	188	245	680
Financial Result	-203	-155	-54	-52	-7	-112	-19	-132	-50	-25	-24	-99
Income before income taxes, continuing operations	1,022	894	242	267	212	722	233	954	197	163	221	581
Income taxes	-292	-186	-27	-74	-54	-155	-26	-180	-57	-34	-69	-160
Income after taxes, continuing operations	730	708	215	193	158	567	207	774	140	129	152	421
Income after taxes, discontinued operations	0	246	29	40	1,326	1,395	-43	1,353	-6	-11	-	-18
Income after taxes	730	954	244	233	1,484	1,962	164	2,127	134	118	152	403
thereof attributable to non-controlling interests	17	22	5	5	5	17	4	21	4	4	3	10
Shareholders of EVONIK Industries AG (net income)	713	932	239	228	1,479	1,945	160	2,106	130	114	149	393
EPS	1.53	2.00	0.51	0.49	3.17	4.17	0.34	4.52	0.28	0.24	0.32	0.84

Group Adjusted Income Statement

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Sales	14,383	13,267	3,287	3,306	3,232	9,824	3,284	13,108	3,243	2,827	2,917	8,986
Adjusted EBITDA	2,357	2,150	539	566	543	1,647	505	2,153	513	456	519	1,488
Depreciation and amortization	-871	-789	-224	-226	-250	-699	-252	-952	-240	-254	-250	-744
Adjusted EBIT	1,486	1,361	315	340	293	948	253	1,201	273	202	269	744
Adjusted net financial result	-176	-151	-53	-51	-63	-165	-19	-185	-51	-25	-34	-110
Depreciation and amortization on intangible assets	129	143	32	33	35	100	36	136	33	38	38	107
Adjusted Income before income taxes, continuing operations	1,439	1,353	294	322	265	883	270	1,152	255	215	273	741
Adjusted income taxes, continuing operations	-415	-317	-40	-90	-65	-195	-34	-229	-70	-51	-84	-204
Adjusted income after taxes	1,024	1,036	254	232	200	688	236	923	185	164	189	537
Adjusted non-controlling interest	-17	-22	-5	-5	-5	-17	-5	-21	-4	-4	-3	-10
Adjusted net income	1,007	1,014	249	227	195	671	231	902	181	160	186	527
Adjusted EPS	2.16	2.18	0.53	0.49	0.42	1.44	0.50	1.94	0.39	0.34	0.40	1.13

Adjustments

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Q4 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Restructuring	-25	-204	-4	-8	-6	-18	0	-18	-1	-3	-25	-29
Impairment losses/reversal of impairment losses	-82	7	-13	0	-34	-47	0	-47	0	0	-2	-2
Acquisition / divestment of shareholdings	-89	-31	-4	-4	-17	-25	-5	-30	-22	-1	-9	-32
Other	-65	-84	2	-9	-17	-24	4	-20	-3	-10	12	-1
=Adjustments	-261	-312	-19	-21	-74	-114	-1	-115	-26	-14	-24	-64

Group Balance Sheet

Assets

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020
Intangible assets	6,105	6,134	5,909	5,828	5,955	5,858	6,241	6,068	5,904
Property, plant and equipment	6,495	6,785	6,309	6,287	6,349	6,435	6,589	6,568	6,492
Right of use assets (capitalized leasing)			608	601	595	640	691	667	643
Investments recognized at equity	47	46	37	39	42	45	55	73	76
Financial assets	327	233	225	234	223	625	516	556	571
Deferred tax assets	1,226	1,419	1,340	1,568	1,947	1,718	1,694	1,719	1,792
Other income tax assets	14	16	15	12	10	12	12	12	13
Other receivables	296	56	49	49	53	82	82	116	119
Non-current assets	14,510	14,689	14,492	14,618	15,174	15,415	15,880	15,779	15,610
Inventories	2,038	2,304	2,096	2,090	2,087	1,884	1,983	2,080	1,965
Other income tax assets	154	180	182	194	217	325	334	215	148
Trade accounts receivable	1,755	1,686	1,716	1,644	1,653	1,569	1,678	1,464	1,455
Other receivables	313	295	290	332	447	387	437	301	283
Financial assets	166	140	114	88	1,298	1,278	1,141	944	766
Cash and cash equivalents	1,004	988	1,079	529	1,532	1,165	999	864	1,043
Current assets	5,430	5,593	5,477	4,897	7,234	6,608	6,572	5,868	5,660
Assets held for sale	0	0	1,554	1,588	0	0	0	0	0
Current assets	5,430	5,593	7,031	6,485	7,234	6,608	6,572	5,868	5,660
Total assets	19,940	20,282	21,523	21,103	22,408	22,023	22,452	21,647	21,170

Liabilities

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020
Issued capital	466	466	466	466	466	466	466	466	466
Reserves	6,965	7,263	7,427	6,906	7,970	8,504	8,675	8,331	7,828
Equity attributable to shareholders of Evonik Industries AG	7,431	7,729	7,893	7,372	8,436	8,970	9,141	8,797	8,294
Equity attributable to non-controlling interests	88	96	97	96	100	90	89	88	87
Total equity	7,519	7,825	7,990	7,468	8,536	9,060	9,230	8,885	8,381
Provisions for pensions and other post-employment benefits	3,817	3,732	3,447	3,804	4,640	3,967	3,787	3,994	4,274
Other provisions	788	855	815	800	814	779	773	774	765
Deferred tax liabilities	541	557	494	500	494	537	555	523	552
Other income tax liabilities	225	223	246	267	431	320	298	309	315
Financial liabilities	3,706	3,689	4,187	4,181	3,660	3,713	3,171	3,628	3,595
Other payables	57	47	73	73	88	93	111	110	134
Non-current liabilities	9,134	9,103	9,262	9,625	10,127	9,409	8,695	9,338	9,635
Other provisions	968	1,047	1,042	684	749	778	824	603	644
Other income tax liabilities	50	64	62	43	106	59	55	71	53
Financial liabilities	438	395	525	589	1,009	918	1,785	1,138	1,034
Trade accounts payable	1,449	1,493	1,336	1,336	1,284	1,324	1,294	1,201	1,105
Other payables	382	355	382	422	597	475	569	411	418
	3,287	3,354	3,347	3,074	3,745	3,554	4,527	3,424	3,254
Liabilities associated with assets held for sale	0	0	924	936	0	0	0	0	0
Current liabilities	3,287	3,354	4,271	4,010	3,745	3,554	4,527	3,424	3,254
Total equity and liabilities	19,940	20,282	21,523	21,103	22,408	22,023	22,452	21,647	21,170

Group Cash Flow Statement

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	9M 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	9M 2020
Income before financial result and income taxes, continuing operations = EBIT	1,225	1,049	296	319	219	834	1,086	247	188	245	680
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	923	787	221	227	286	734	984	240	256	254	750
Result from investments recognized at equity	-10	-10	10	-5	-2	3	-5	-5	-2	-6	-13
Gains/losses on disposal of non current assets	-73	3	-5	0	4	-1	-13	15	-5	-13	-3
Change in inventories	-97	-242	-65	-15	23	-57	129	-90	-123	78	-135
Change in trade accounts receivable	-56	75	-166	40	103	-23	41	-94	198	-46	58
Change in trade accounts payable and current advance payments received from customers	192	15	27	6	-123	-90	-62	-18	-98	-70	-186
Change in provisions for pensions and other post-employment benefits	-202	-229	-23	-12	-34	-69	-60	18	3	1	22
Change in other provisions	-6	158	24	-367	46	-297	-294	23	-224	41	-160
Change in miscellaneous assets/liabilities	22	26	80	-2	6	85	-15	54	-10	39	83
Cash inflows/outflows from interest	-65	-	-	-	-	-	-	-	-	-	-
Cash inflows from dividends	11	12	2	5	3	10	15	13	10	0	23
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-128	-128	-245	-	-	-	-
Cash inflows/outflows for income taxes	-313	-170	-67	-78	0	-145	-209	-106	92	12	-2
Cash flow from operating activities, continuing operations	1,551	1,474	334	118	403	856	1,352	297	285	535	1,117
Cash flow from operating activities, discontinued operations	0	286	25	14	52	91	-31	0	-9	0	-9
Cash flow from operating activities	1,551	1,760	359	132	455	947	1,321	297	276	535	1,108
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-1,040	-948	-175	-182	-210	-567	-880	-184	-189	-223	-596
Cash outflows for investments in shareholdings	-4,137	-39	-10	-9	-34	-53	-427	-298	-11	-4	-313
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	12	16	9	0	10	19	25	6	6	20	32
Cash inflows/outflows from divestments of businesses and other shareholdings	-10	68	0	-5	2,205	2,199	2,208	40	5	20	20
Cash inflows/outflows relating to securities, deposits and loans	17	-24	-13	0	-1,203	-1,216	-1,223	146	222	212	580
Cash inflows from interest	-	43	4	12	5	21	52	6	8	13	27
Cash flow from investing activities, continuing operations	-5,181	-884	-185	-184	773	403	-245	-284	41	38	-205
Cash flow from investing activities, discontinued operations	0	-89	-10	-21	-16	-47	-47	0	0	0	-
Cash flow from investing activities	-5,181	-973	-195	-205	757	356	-292	-284	41	38	-205
Cash inflows/outflows relating to capital contributions	0	2	0	1	3	4	4	3	-1	0	2
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	0	-536	-	-536	-536	0	-266	-270	-536
Cash outflows for dividends to non-controlling interests	-14	-16	-5	-5	-1	-11	-12	-6	-7	0	-13
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	0	0	0	0	0	0	0	0	0	0
Cash outflows for the purchase of treasury shares	-19	-17	-11	-6	0	-17	-17	-15	-1	0	-16
Cash inflows from the sale of treasury shares	20	13	0	13	0	13	13	0	12	0	12
Cash inflows from the addition of financial liabilities	700	61	45	172	-64	153	110	228	631	45	904
Cash outflows for repayment of financial liabilities	-201	-192	-81	-72	-132	-285	-295	-356	-778	-170	-1,304
Cash inflows/outflows in connection with financial transactions	73	8	-1	16	-6	9	-1	-8	-15	23	0
Cash outflows for interest	-	-121	-18	-44	-19	-81	-114	-15	-23	-12	-50
Cash flow from financing activities, continuing operations	23	-798	-71	-461	-219	-751	-848	-169	-448	-384	-1,001
Cash flow from financing activities, discontinued operations	0	-3	-2	-2	-4	-8	-8	0	0	0	-
Cash flow from financing activities	23	-801	-73	-463	-223	-759	-856	-169	-448	-384	-1,001
Change in cash and cash equivalents	-3,607	-14	91	-536	989	544	173	-156	-131	189	-98
Cash and cash equivalents as of beginning of period	4,623	1,004	988	1,085	540	988	988	1,165	999	864	1,165
Change in cash and cash equivalents	-3,607	-14	91	-536	989	544	173	-156	-131	189	-98
Changes in exchange rates and other changes in cash and cash equivalents	-12	-2	6	-9	3	0	4	-10	-4	-10	-24
Cash and cash equivalents as of end of period	1,004	988	1,085	540	1,532	1,532	1,165	999	864	1,043	1,043
Cash and cash equivalents included in assets held for sale	0	0	-6	-11	0	0	0	0	0	0	0
Cash and cash equivalents as on the balance sheet as of end of period	1,004	988	1,079	529	1,532	1,532	1,165	999	864	1,043	1,043

Group Net Financial Position

in € million	Year FY 2017	Year FY 2018	Q1 2019	Q2 2019	Q3 2019	Year FY 2019	Q1 2020	Q2 2020	Q3 2020	Notes of the annual report 2019
Non-current financial liabilities	-3,694	-3,683	-4180	-4179	-3654	-3,712	-3,169	-3,627	-3,593	(6.12)
Current financial liabilities	-351	-230	-343	-458	-825	-806	-1,661	-1,063	-980	(6.12)
Financial debt	-4,045	-3,913	-4,523	-4,637	-4,479	-4,518	-4,830	-4,690	-4,573	
- Cash and cash equivalents	1,004	988	1,079	529	1,532	1,165	999	864	1,043	(7)
- Current securities	9	8	8	7	1,188	1,203	1,031	820	609	
- Other financial assets	9	10	17	20	25	9	22	12	11	
Financial assets	1,022	1,006	1,104	556	2,745	2,377	2,052	1,696	1,663	
Net financial debt/cash as stated on the balance sheet	-3,023	-2,907	-3,419	-4,081	-1,734	-2,141	-2,778	-2,994	-2,910	
Net financial debt/cash, discontinued operations			-18	-12						
Net financial debt/cash including discontinued operations		-2,907	-3,437	-4,093	-1,734	-2,141	-2,778	-2,994	-2,910	

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TFS Assessments	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.